Patent US4863928A successfully refreshed from Google Patents.
US4863928A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treatment for arthritic and inflammatory diseases
Assignee: Teva Branded Pharmaceutical Products R&D Inc
•
Filing: 1989-01-04
•
Granted: 1989-09-05
•
Expires: 2009-01-04
Abstract
Abstract A method of treating a human or animal patient suffering from an arthritic disease or associated inflammatory disease comprises daily administration to such patient of from about 1 to about 100 mg of the narcotic antagonists nalmefene or naltrexone. The nalmefene or naltrexone may be administered in equally divided doses from one to four times daily, preferably by the oral route. Parental administration may be utilized where suitable.
Inventors
- 👤 David C. Atkinson
- 👤 Jack Fishman
- 👤 Fred P. Sherman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 12:27
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/485; A61P; A61P29/00
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
37 words
A method of treating a human or animal patient suffering from an arthritic disease or associated inflammatory disease comprising the daily administration to the patient of from about 1 to about 100 mg of nalmefene or naltrexone.
Claim 2
Independent Claim
37 words
A method of treating a human or animal patient suffering from an arthritic disease or associated inflammatory disease comprising the daily administration to the patient of from about 1 to about 100 mg of nalmefene or naltrexone.
Claim 3
Dependent Claim
37 words
A method according to claim 1 wherein said patient is suffering from an arthritic disease selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriatic arthritis, acute gouty arthritis and Reiter's syndrome.
Claim 4
Dependent Claim
24 words
A method according to claim 1 wherein said patient is suffering from an inflammatory disease selected from the group consisting of bursitis and tendinitis.
Claim 5
Dependent Claim
17 words
A method according to claim 1 wherein the nalmefene or naltrexone is administered to the patient orally.
Claim 6
Dependent Claim
42 words
A method according to claim 4 wherein the nalmefene or naltrexone is administered to the patient in an oral dosage form comprising a tablet, capsule, caplet or liquid containing from about 0.5 to about 50.0 mg of nalmefene or naltrexone per unit.
Claim 7
Dependent Claim
17 words
A method according to claim 1 wherein the nalmefene or naltrexone is administered to the patient parenterally.
Claim 8
Dependent Claim
24 words
A method according to claim 6 wherein the nalmefene or naltrexone is administered to the patient by the subcutaneous, intramuscular, intravenous or intra-articular routes.
Claim 9
Dependent Claim
22 words
A method according to claim 1 wherein the nalmefene or naltrexone is administered to the patient from one to four times daily.
Claim 10
Dependent Claim
22 words
A method according to claim 8 wherein the nalmefene or naltrexone is administered to the patient from one to two times daily.
Claim 11
Dependent Claim
40 words
A method according to claim 9 wherein 1 mg of nalmefene or naltrexone is administered to the patient twice daily for an initial period, after which the dosage amount is gradually increased to a maximum of 50 mg twice daily.
References Cited (Backward Citations)
US4760069A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-09-04 | 1993-03-06 | 1993-09-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-09-04 | 1997-03-06 | 1997-09-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-09-04 | 2001-03-06 | 2001-09-05 | $7700.00 | Window Closed / Lapsed |